Therapeutic applications of the gaseous mediators carbon monoxide and hydrogen sulfide

被引:47
作者
Bannenberg, Gerard L. [1 ]
Vieira, Helena L. A. [2 ]
机构
[1] CSIC, Ctr Nacl Biotecnol, Dept Plant Mol Genet, Madrid 28049, Spain
[2] ITQB UNL IBET, Anim Cell Technol Lab, P-2780901 Oeiras, Portugal
关键词
carbon monoxide; carbon monoxide releasing molecules; gasotransmitters; hydrogen sulfide; hydrogen sulfide releasing molecules; PROTEIN-KINASE PATHWAY; SMOOTH-MUSCLE RELAXANT; REPERFUSION LUNG INJURY; NITRIC-OXIDE; HEME OXYGENASE-1; ENDOGENOUS PRODUCTION; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; IN-VITRO; INHIBITION;
D O I
10.1517/13543770902858824
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background. Hydrogen sulfide (H2S) and carbon monoxide (CO) are endogenously produced gaseous autacoids that regulate a number of physiological processes, including the inflammatory response, cell death and proliferation, neural transmission and smooth muscle tone. Objective/methods: The current review aims to provide a comprehensive overview of all recent patent applications that address the potential therapeutic applications of CO and H2S. Results/conclusion: Beyond the direct administration of CO and H2S, this review highlights the therapeutic applications of a variety of gas-releasing molecules that are being developed to deliver CO and H2S to diseased tissues at therapeutic doses. The term autacoid, which, in addition to its pharmacological use to describe a locally-acting hormone, literally translates from Greek as 'self-drug', seems to particularly well describe the current approach to capture the potential therapeutic use of these two gasotransmitters. In summary, we can conclude that there is a markedly growing interest in harnessing the tissue-protective actions of CO and H2S.
引用
收藏
页码:663 / 682
页数:20
相关论文
共 125 条
[1]  
Abe K, 1996, J NEUROSCI, V16, P1066
[2]  
AGA AB, 2005, Patent No. 2005067945
[3]  
AIR LIQUIDE SANTE IN, 2002, Patent No. 0209731
[4]  
AIR LIQUIDE SANTE IN, 2002, Patent No. 2816212
[5]  
ALFAMA INC, 2008, Patent No. 20080026984
[6]  
ALFAMA INC, 2003, Patent No. 2003066067
[7]  
ALFAMA INC, 2007, Patent No. 2007073225
[8]   Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide? [J].
Ali, M. Y. ;
Ping, C. Y. ;
Mok, Y-Y P. ;
Ling, L. ;
Whiteman, M. ;
Bhatia, M. ;
Moore, P. K. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 149 (06) :625-634
[9]   Low-dose carbon monoxide reduces airway hyperresponsiveness in mice [J].
Ameredes, BT ;
Otterbein, LE ;
Kohut, LK ;
Gligonic, AL ;
Calhoun, WJ ;
Choi, AMK .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2003, 285 (06) :L1270-L1276
[10]  
ANTIBE THERAPEUTICS, 2008, Patent No. 2008009118